- Insider Monkey
Do Hedge Funds Love HUTCHMED (China) Limited (HCM)?
The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
- infocast
和黃醫藥(00013)獲納入若干恒生指數之成分股
和黃醫藥(00013)宣布，公司被納入恒生綜合指數、恒生醫療保健指數、恒生香港上市生物科技指數等7項香港上市股票指數；另外亦被納入6項跨市場指數，包括恒生滬深港通中國500指數等，今年9月6日正式生效。 (ST)
- AASTOCKS
《大行報告》麥格理首予和黃醫藥(00013.HK)「跑贏大市」評級 目標價83.31元
麥格理發表研究報告，首予和黃醫藥(00013.HK)(HCM.US)H股「跑贏大市」評級，目標價83.31元，屬生科板塊首選股之一。
